Immutep Ltd
NASDAQ:IMMP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.41
3.08
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
IMMP
stock under the Base Case scenario is
18.56
USD.
Compared to the current market price of 3.08 USD,
Immutep Ltd
is
Undervalued by 83%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Immutep Ltd.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Delays or failures in Immutep’s lead product candidate eftilagimod alpha could undermine its pipeline credibility, especially given the high stakes of LAG-3–targeted therapies and the company’s limited clinical-stage assets.
A high cash burn rate relative to Immutep’s available funding threatens near-term liquidity, raising concerns that additional capital raises or dilutive share issuances may be necessary to sustain operations.
Intensifying competition in the LAG-3 immunotherapy space from larger biotech and pharmaceutical players puts pressure on Immutep’s ability to differentiate its treatments and secure favorable partnership terms.
Eftilagimod alpha’s encouraging clinical data in combination with checkpoint inhibitors suggests a strong potential to become a new standard in immuno-oncology, particularly for challenging cancers like metastatic breast cancer.
Multiple partnerships and licensing agreements with established pharmaceutical companies like Merck provide Immutep with both external validation and a path to milestone payments that could support long-term development efforts.
An expanding pipeline of LAG-3–focused candidates beyond eftilagimod alpha leverages Immutep’s deep expertise in immuno-oncology, potentially positioning the company at the forefront of next-generation cancer treatments.
Revenue & Expenses Breakdown
Immutep Ltd
Balance Sheet Decomposition
Immutep Ltd
| Current Assets | 149.1m |
| Cash & Short-Term Investments | 129.7m |
| Receivables | 10.9m |
| Other Current Assets | 8.5m |
| Non-Current Assets | 7.9m |
| PP&E | 569.5k |
| Intangibles | 7.2m |
| Other Non-Current Assets | 116.5k |
| Current Liabilities | 12.8m |
| Accounts Payable | 5.5m |
| Accrued Liabilities | 814k |
| Other Current Liabilities | 6.4m |
| Non-Current Liabilities | 589.3k |
| Long-Term Debt | 314.9k |
| Other Non-Current Liabilities | 274.4k |
Free Cash Flow Analysis
Immutep Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Immutep Ltd
|
Revenue
|
60.1k
AUD
|
|
Operating Expenses
|
-70.2m
AUD
|
|
Operating Income
|
-70.1m
AUD
|
|
Other Expenses
|
8.7m
AUD
|
|
Net Income
|
-61.4m
AUD
|
IMMP Profitability Score
Profitability Due Diligence
Immutep Ltd's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Immutep Ltd's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
IMMP Solvency Score
Solvency Due Diligence
Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Immutep Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMMP Price Targets Summary
Immutep Ltd
According to Wall Street analysts, the average 1-year price target for
IMMP
is 3.3 USD
with a low forecast of 2.79 USD and a high forecast of 4.01 USD.
Dividends
Current shareholder yield for
IMM is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IMMP
stock under the Base Case scenario is
18.56
USD.
Compared to the current market price of 3.08 USD,
Immutep Ltd
is
Undervalued by 83%.